HC Wainwright Issues Positive Forecast for OptiNose (NASDAQ:OPTN) Stock Price

OptiNose (NASDAQ:OPTN - Get Free Report) had its price target increased by equities researchers at HC Wainwright from $5.00 to $18.00 in a report released on Friday, Marketbeat Ratings reports. The firm currently has a "buy" rating on the stock. HC Wainwright's price target would indicate a potential upside of 176.92% from the stock's previous close.

Separately, Piper Sandler decreased their target price on OptiNose from $45.00 to $15.00 and set an "overweight" rating on the stock in a research note on Wednesday, November 13th.

OptiNose Stock Performance

Shares of OPTN traded down $0.20 during mid-day trading on Friday, reaching $6.50. The stock had a trading volume of 28,035 shares, compared to its average volume of 47,918. The firm has a market cap of $980.39 million, a price-to-earnings ratio of -23.21 and a beta of -0.16. The business has a fifty day moving average of $7.81 and a 200 day moving average of $11.86. OptiNose has a 12 month low of $4.82 and a 12 month high of $31.50.

Hedge Funds Weigh In On OptiNose

Institutional investors have recently added to or reduced their stakes in the company. XTX Topco Ltd bought a new position in shares of OptiNose during the 2nd quarter valued at approximately $88,000. GSA Capital Partners LLP bought a new position in OptiNose during the third quarter valued at $61,000. Squarepoint Ops LLC raised its position in shares of OptiNose by 173.7% during the 2nd quarter. Squarepoint Ops LLC now owns 171,610 shares of the company's stock valued at $178,000 after buying an additional 108,903 shares in the last quarter. State Street Corp lifted its stake in shares of OptiNose by 14.2% in the 3rd quarter. State Street Corp now owns 341,303 shares of the company's stock valued at $229,000 after purchasing an additional 42,500 shares during the last quarter. Finally, Rice Hall James & Associates LLC lifted its position in OptiNose by 15.4% in the third quarter. Rice Hall James & Associates LLC now owns 1,140,626 shares of the company's stock worth $764,000 after buying an additional 152,435 shares during the last quarter. Hedge funds and other institutional investors own 85.60% of the company's stock.

About OptiNose

OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device.